Pediatric Atopic Dermatitis Dialogues at AAD 2024

Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.

Brian Kim, MD, underscores the critical gap in addressing severe itch in atopic dermatitis, often overshadowed by the visible manifestations of skin rash.

Alexandra Golant, MD, explains why she is confident in the latest safety and efficacy data from ruxolitinib trials to treat pediatric patients with atopic dermatitis.

Alexandra Golant, MD, shares how sleep improvement is measured and the difference an effective treatment makes for the patient’s entire family.

Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.

Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.

Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.

Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.